Skip to main content

Research

The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

Can more type 2 therapies be used for type 1 diabetes?
Part 1 of our interview with the Helmsley Charitable Trust’s David Panzirer and T1D Exchange's Dana Ball.
Kelly’s transformative experience wearing an artificial pancreas for five days.
On November 1, Dr. Ed Damiano presented results from the Beacon Hill study and Summer Camp study of the bionic pancreas at Carb DM ’s Second Anniversary. For more...
On April 9, Lilly and T1D Exchange announced a five-year research collaboration on projects designed to improve the health and wellbeing of people with type 1 diabetes...
In May, Lexicon announced its results of LX4211, an SGLT-1/SGLT-2 inhibitor. The phase 2 trial finished its open-label, pioneer section, which showed a decrease in...
Halozyme announced recently that Yale researchers have started a 20-patient artificial pancreas study (which is still recruiting) that will test the ability of...
On April 24, Hyperion Therapeutics announced that it would acquire Andromeda Biotech. Andromeda is focused on the development of a first-in-class immune therapy for new...
TrialNet is bringing their services online, making it easier for people to be screened for type 1 diabetes. Family members of those with type 1 diabetes can answer an...
On November 4, JDRF announced a partnership with Pfizer’s Centers for Therapeutic Innovation (CTI) to support what they call promising diabetes research in collaboration...
At ADA this year, type 2 drugs for type 1 diabetes show lots of promise. Plus, the latest exciting data on the Medtronic Veo and hypoglycemia.
The National Institutes of Health (NIH) recently announced it will provide millions of dollars in funding for the first large-scale clinical trial to determine whether...
A whole new approach to treating type 2 diabetes at diagnosis, a new type of metformin, and the benefit of adding a GLP-1 agonist to insulin.
You call that an artificial pancreas? The pathway to closed loop system.
On July 10, the JDRF and 161 delegates for the Children’s Congress traveled to Capitol Hill inWashington, D.C. to call for support of type 1 diabetes research funding...
Kelly’s experience in UVA’s overnight closed loop trial makes for fantastic dreams.
Are all carbs created equal? Adam learns why 30 grams of carbs is NOT always 30 grams of carbs…
On December 2, the influential Helmsley Charitable Trust (HCT), one of the world’s largest funders of type 1 diabetes research – and the 12th largest private foundation...
Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
On September 24, JAMA published a paper on long-term trends in the number of people with diabetes in the United States from 1980 to 2012. The results showed a leveling-...

Pages